Zinc Chemoprevention of Arsenic Co-Carcinogenesis

锌对砷协同致癌作用的化学预防

基本信息

项目摘要

DESCRIPTION (provided by applicant): There is strong evidence that in addition to the known direct carcinogenic actions of high arsenic concentrations, low, non-carcinogenic levels of arsenic synergize with other DNA-damaging agents such as benzo[a]pyrene and ultraviolet radiation (UVR) to enhance carcinogenesis. This observation has led to the identification of arsenic as a co-carcinogen. One mode of action to account for arsenic co-carcinogenesis is inhibition of DNA repair proteins containing zinc finger DNA binding motifs. Research from our lab demonstrates that: i) zinc finger proteins with e3 cysteine residues are direct molecular targets for arsenite binding, including xeroderma pigmentosum group A (XPA) and poly(ADP-ribose)polymerase (PARP)-1, which are the critical proteins for nucleotide excision repair (NER) and base excision repair (BER) respectively; ii) low levels of arsenite enhance UVR-induced photoproducts and oxidative DNA damage; and iii) supplemental zinc prevents arsenite effects on PARP-1 inhibition, enhancement of UVR-induced DNA damage and mutations. We hypothesize that zinc supplement will prevent arsenite enhancement of UVR-induced skin tumors by restoring the DNA repair capabilities in both BER and NER pathways. The proposed study will address a novel mechanism by which zinc may act to prevent arsenic-augmented carcinogenesis through interaction with distinct molecular targets in DNA repair pathways. In Aim 1, we will use multiple analytical approaches to definitively examine the competitive interaction of arsenite and zinc with synthetic peptides representing the PARP-1 and XPA zinc finger domains and with purified protein. These findings will be coupled with functional assays to establish the consequences of any identified differences in arsenite affinity for target proteins and zinc interactions. Aim 2 will analyze PARP-1 and XPA isolated from treated cells to measure arsenic and zinc binding to protein and the corresponding functional consequences to reveal the specific mechanism by which zinc reverses the arsenic effects. In Aim 3, we will validate PARP-1 and XPA as arsenic targets in vivo using biochemical methods, and test the hypothesis that zinc will prevent arsenic enhancement of UVR-induced DNA damage and skin tumors. The outcomes from the proposed studies are expected to demonstrate the capability of zinc to restore PARP-1 and XPA activity leading to improved genomic integrity and a decrease in the arsenic contribution to co-carcinogenesis. Although zinc has been considered chemoprotective largely through its reported general antioxidant activities, this proposal is innovative by focusing on a novel mechanism by which zinc prevents arsenite binding with specific zinc finger DNA repair protein targets, thus reversing the arsenite inhibition of DNA repair. This study will provide the solid foundations for a clear mechanistic understanding of how supplemental zinc reduces arsenic co-carcinogenesis, and provide the proof of principle for the potential of zinc supplement to prevent arsenic co-carcinogenesis. If validated, supplemental zinc could represent a low cost and easily implemented strategy for chemoprevention in arsenic exposed populations.
描述(由申请人提供):有强有力的证据表明,除了已知的高砷浓度的直接致癌作用外,低、非致癌水平的砷与其他DNA损伤剂(如苯并[a]芘和紫外线辐射(UVR))协同作用,以增强致癌作用。这一观察结果导致砷被确定为一种共同致癌物。解释砷共致癌作用的一种作用模式是抑制含有锌指DNA结合基序的DNA修复蛋白。我们实验室的研究表明:i)具有e3半胱氨酸残基的锌指蛋白是亚砷酸盐结合的直接分子靶点,包括A组着色性干皮病(XPA)和多聚(ADP-核糖)聚合酶(PARP)-1,它们分别是核苷酸切除修复(NER)和碱基切除修复(BER)的关键蛋白;和iii)补充锌防止亚砷酸盐对PARP-1抑制、增强UVR诱导的DNA损伤和突变的影响。我们假设,锌补充剂将通过恢复BER和NER途径中的DNA修复能力来防止亚砷酸盐增强UVR诱导的皮肤肿瘤。这项研究将提出一种新的机制,锌可以通过与DNA修复途径中不同的分子靶点相互作用来防止砷增强的致癌作用。在目标1中,我们将使用多种分析方法来明确检查亚砷酸盐和锌与代表PARP-1和XPA锌指结构域的合成肽以及与纯化蛋白质的竞争性相互作用。这些发现将与功能测定相结合,以确定任何已确定的亚砷酸盐对靶蛋白和锌相互作用的亲和力差异的后果。目的2将分析从处理的细胞中分离的PARP-1和XPA,以测量砷和锌与蛋白质的结合以及相应的功能后果,以揭示锌逆转砷效应的具体机制。在目标3中,我们将使用生物化学方法验证PARP-1和XPA作为体内砷靶点,并测试锌将防止砷增强紫外线诱导的DNA损伤和皮肤肿瘤的假设。预计拟议研究的结果将证明锌恢复PARP-1和XPA活性的能力,从而改善基因组完整性并降低砷对共致癌作用的贡献。虽然锌已被认为是化学保护主要是通过其报告的一般抗氧化活性,这一建议是创新的,通过集中在一个新的机制,锌防止砷与特定的锌指DNA修复蛋白的目标结合,从而逆转砷抑制DNA修复。本研究将为明确补充锌减少砷致癌作用的机制提供坚实的基础,并为补充锌预防砷致癌作用的潜力提供原则证据。如果得到验证,补充锌可能是一种低成本和易于实施的战略,砷暴露人群的化学预防。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

LAURIE G HUDSON其他文献

LAURIE G HUDSON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('LAURIE G HUDSON', 18)}}的其他基金

Pilot Project Core
试点项目核心
  • 批准号:
    10393303
  • 财政年份:
    2022
  • 资助金额:
    $ 31.44万
  • 项目类别:
Pilot Project Core
试点项目核心
  • 批准号:
    10689705
  • 财政年份:
    2022
  • 资助金额:
    $ 31.44万
  • 项目类别:
Illuminating the functions and translational potential of CDC42BP/MRCK kinases in ovarian cancer
阐明 CDC42BP/MRCK 激酶在卵巢癌中的功能和翻译潜力
  • 批准号:
    10216717
  • 财政年份:
    2021
  • 资助金额:
    $ 31.44万
  • 项目类别:
Mutational Signatures of a Combined Environmental Exposure: Arsenic and Ultraviolet Radiation
综合环境暴露的突变特征:砷和紫外线辐射
  • 批准号:
    10844717
  • 财政年份:
    2020
  • 资助金额:
    $ 31.44万
  • 项目类别:
Mutational Signatures of a Combined Environmental Exposure: Arsenic and Ultraviolet Radiation
综合环境暴露的突变特征:砷和紫外线辐射
  • 批准号:
    10330581
  • 财政年份:
    2020
  • 资助金额:
    $ 31.44万
  • 项目类别:
Biomarkers and mechanisms of metal and mixed metal exposures
金属和混合金属暴露的生物标志物和机制
  • 批准号:
    10707512
  • 财政年份:
    2017
  • 资助金额:
    $ 31.44万
  • 项目类别:
Biomarkers and mechanisms of metal and mixed metal exposures
金属和混合金属暴露的生物标志物和机制
  • 批准号:
    10353202
  • 财政年份:
    2017
  • 资助金额:
    $ 31.44万
  • 项目类别:
Zinc Chemoprevention of Arsenic Co-Carcinogenesis
锌对砷协同致癌作用的化学预防
  • 批准号:
    8762020
  • 财政年份:
    2014
  • 资助金额:
    $ 31.44万
  • 项目类别:
Arsenic co-carcinogenesis with UVR: nitrosation and oxidation of target proteins
砷与 UVR 的协同致癌作用:目标蛋白的亚硝化和氧化
  • 批准号:
    8856568
  • 财政年份:
    2012
  • 资助金额:
    $ 31.44万
  • 项目类别:
Capitalizing on NSAID enantiomer selectivity for cancer prevention and therapy(PQ
利用 NSAID 对映体选择性进行癌症预防和治疗 (PQ
  • 批准号:
    8625502
  • 财政年份:
    2012
  • 资助金额:
    $ 31.44万
  • 项目类别:

相似海外基金

Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
  • 批准号:
    10591918
  • 财政年份:
    2023
  • 资助金额:
    $ 31.44万
  • 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
  • 批准号:
    23K15383
  • 财政年份:
    2023
  • 资助金额:
    $ 31.44万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
  • 批准号:
    23H03556
  • 财政年份:
    2023
  • 资助金额:
    $ 31.44万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
  • 批准号:
    23K17212
  • 财政年份:
    2023
  • 资助金额:
    $ 31.44万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
  • 批准号:
    22H03519
  • 财政年份:
    2022
  • 资助金额:
    $ 31.44万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
  • 批准号:
    563657-2021
  • 财政年份:
    2022
  • 资助金额:
    $ 31.44万
  • 项目类别:
    Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10521849
  • 财政年份:
    2022
  • 资助金额:
    $ 31.44万
  • 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10671022
  • 财政年份:
    2022
  • 资助金额:
    $ 31.44万
  • 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
  • 批准号:
    10670918
  • 财政年份:
    2022
  • 资助金额:
    $ 31.44万
  • 项目类别:
Downsides of downhill: The adverse effects of head vibration associated with downhill mountain biking on visuomotor and cognitive function
速降的缺点:与速降山地自行车相关的头部振动对视觉运动和认知功能的不利影响
  • 批准号:
    2706416
  • 财政年份:
    2022
  • 资助金额:
    $ 31.44万
  • 项目类别:
    Studentship
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了